Blue Cross Blue Shield · Tecartus · US health-plan appeal rights

Tecartus denied due to quantity / dose limits by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Tecartus denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

FDA-approved indication: r/r mantle cell lymphoma after >=2 prior lines including a BTK inhibitor (Jul 2020 ZUMA-2) OR adult (>=18) r/r B-cell precursor ALL (Oct 2021 ZUMA-3). Age >=18. ECOG 0-1. ANC >=1000, plt >=75K, LVEF >=50%, CrCl >=60, AST/ALT <2.5x ULN, total bili <1.5. No active CNS disease. Administered at FACT-accredited REMS-certified ATC. Bridging + Flu/Cy LD bundled.

Source policy: BCBS Federal Employee Program Medical Policy — Brexucabtagene Autoleucel (Tecartus)

What works in the appeal

ZUMA-2 (Wang NEJM 2020) — Tecartus 87% ORR / 62% CR in r/r MCL post-BTKi → FDA Jul 24 2020. ZUMA-3 (Shah Lancet 2021) — Tecartus 71% CR/CRi in adult r/r B-ALL → FDA Oct 1 2021. NCCN ALL v2.2024 + NCCN B-cell Lymphomas v6.2024 list Tecartus as preferred regimen. Allo-HSCT carries 20-30% TRM vs Tecartus much lower TRM; many B-ALL patients ineligible for allo-HSCT due to age/comorbidity/no donor. ZUMA-3 entry criteria included MRD+ relapse; MRD+ qualifies as r/r disease per NCCN + IWG. Prior BTKi requirement met by any covalent or non-covalent BTKi exposure.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield Tecartus

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.